Skip Navigation

Cardiovascular Research 2005 65(4):770-771; doi:10.1016/j.cardiores.2005.01.009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Petrashevskaya, N. N.
Right arrow Articles by Schwarz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrashevskaya, N. N.
Right arrow Articles by Schwarz, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Peroxisome proliferator-activated receptor β/{delta}: a new antihypertrophic drug target?

Natalia N. Petrashevskaya* and Arnold Schwarz

Institute of Molecular Pharmacology and Biophysics, Department of Surgery, University of Cincinnati College of Medicine, G936 Cardiovascular Research Center, 231 Albert Sabin Way, Cincinnati, OH 45267-0529, United States

* Corresponding author. Tel.: +1 513 558 2374; fax: +1 513 558 1778. Email address: petrasnn@email.uc.edu

Received 6 January 2005; accepted 10 January 2005

The first 10% of the full text of this article appears below.

See article by Planavila et al. [6] (pages 832–841) in this issue.

In the normal adult heart, plasticity of ATP production is provided by coordinated changes in the expression of genes involved in cellular fatty acid (FA) utilization and glucose oxidation. The phenotypes of acquired forms of heart failure in human and animal models are associated with energy substrate changes accompanying a reduced mitochondrial FA oxidative capacity and a shift to glucose metabolism, resembling the fetal metabolic program [1]. High glucose conditions, initially serving as a protective response to support contractile function, stimulate the production of angiotensin II (Ang II), a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Han, J. D. Ritzenthaler, Y. Zheng, and J. Roman
PPAR{beta}/{delta} agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-{kappa}B signals
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1238 - L1249.
[Abstract] [Full Text] [PDF]